Catalyst in the News

See also press releases from Catalyst.

2011

• 11/11 — Journal of Medicinal Chemistry (PDF) A team including Catalyst Scientific Advisor Silverman described CPP-115 preclinical data supporting its use as a treatment for cocaine addiction, its pharmacological target specificity, and its visual safety.

2009

• 11/09 — The American Journal of Psychiatry (PDF)
  Editorial (PDF) A team including Catalyst Scientific Advisors Brodie, Dewey, and Laska reported positive results for Catalyst's 2007 Phase II trial of CPP-109 in Mexico. The paper concludes that vigabatrin may be safe and effective in the treatment of cocaine addiction.

2008

• 11/13/08 — SynapseSynapse reports that vigabatrin, which Catalyst is testing as an addiction treatment, blocks reinstatement of drug-seeking behavior in animals, giving hope for treating relapse to meth­am­phet­a­mine abuse.
• 8/20/08 — SynapseSynapse reports that genetically bred “fat rats” given vigabatrin, which Catalyst is testing as an addiction treatment, experience dramatic weight loss.
• 3/3/08 — Newsweek — (PDF version here) Cover story: "What Addicts Need: Addiction isn't a weakness; it's an illness. Now vaccines and other new drugs may change the way we treat it."

2007

• 12/18/07 — Rodman & Renshaw, transcript (PDF)
  Rodman & Renshaw rates Catalyst "Market Outperform" and sponsors expert panel on the promise of vigabatrin to treat addiction.
• 12/07 — The Ones to Watch (PDF)
  In its quarterly review, Thomson Scientific calls CPP-109 one of "the five most promising drugs entering Phase II trials" from July to September 2007. See page 7
• 7/16/07 — BioCentury
  "Product Development: Down-sizing the High"
• 7/05/07 — TIME magazine
  "How We Get Addicted"
• 2/16/07 — Long Island Newsday
  "Dulling dopamine's kick"
• 1/14/07 — Miami Herald
  "Catalyst focuses on drug to treat addicts"

2005

• 4/21/05 — Senate Testimony
  Nora D. Volkow, MD, Director of NIDA, discusses promise of CPP-109 during "meth­am­phet­a­mine Abuse – Testimony before the Senate Subcommittee on Labor, Health and Human Services, Education, and Related Agencies – Committee on Appropriations"

2004

• 12/10/04 — VentureWire Lifescience
  "Catalyst Looks for $10M Series B as it Plans Clinical Trials"
• 2/15/04 — NIDA Notes"The Long Road to Medication Development: Cocaine Treatment Moves to Clinical Trials"

What’s New

Catalyst has acquired exclusive worldwide rights to commercialize novel GABA aminotransferase inhibitors and derivatives of vi­ga­ba­trin discovered by Northwestern University. More »